Moderna Regains Rights To Respiratory Syncytial Virus Vaccine From Merck - Quick Facts

Moderna, Inc., (MRNA) said it has regained all rights to the respiratory syncytial virus vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. Merck will complete the phase 1 study and transition the program to Moderna.

Moderna also announced the initiation of dosing in the phase 1 study of its solely owned RSV vaccine candidate (mRNA-1345). This phase 1 study includes initial dosing in adults, followed by age de-escalation into children.

Moderna and Merck will continue their ongoing collaboration in cancer vaccines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT